Wara Samar
23rd April 2025
M42 Partners with Juvenescence to Advance AI-Powered Drug Discovery and Longevity Science
M42, a global health leader powered by artificial intelligence (AI), technology, and genomics, has announced a strategic investment and partnership with longevity biotech leader Juvenescence. The announcement was made during Abu Dhabi Global Health Week (ADGHW), held from 15 to 17 April at ADNEC, where M42 serves as a Foundational Partner for the second consecutive year.
This collaboration marks a significant milestone in advancing the prevention and treatment of diseases of high unmet need, both within the UAE and globally, particularly those associated with ageing. It also aligns with M42’s newly launched AI Life Sciences Platform, which aims to redefine the role of AI in healthcare innovation and therapeutic development.
Advancing AI-Powered Drug Discovery
As part of the investment, M42 and Juvenescence will work together to develop a pipeline of AI-enabled therapeutics that extend healthy lifespan and address life-threatening conditions. The partnership leverages M42’s capabilities in genomics, biobanking, and clinical trial infrastructure alongside Juvenescence’s discovery technology and extensive experience in drug development.
M42’s strategic investment will accelerate Juvenescence’s clinical pipeline and bolster its drug development capabilities, underlining the ambition and depth of this collaboration.
“With this investment and partnership, M42 is taking great strides in reinforcing Abu Dhabi’s push as a global nexus for AI-enabled therapeutics and biomedical innovation to tackle local and international health challenges. With Juvenescence, we are unlocking the potential of AI to transform the way we discover and deliver drugs, bringing innovative, life-changing therapies to patients worldwide. This is not just about innovation, it’s about impact – on lives, on science and on the future of health,” said Hasan Jasem Al Nowais, Managing Director and Group Chief Executive Officer at M42, in a statement.
Supporting Abu Dhabi’s Vision for Health Innovation
The collaboration supports the broader strategy of expanding AI-enabled therapeutics in alignment with Abu Dhabi’s vision of becoming a global hub for longevity science and next-generation drug development. A Joint Steering Committee, comprised of senior executives from both companies, will oversee the partnership’s execution, including potential collaborations with global academic and research organisations and further development of M42’s biotechnology strategy in Abu Dhabi.
“Our partnership with Juvenescence is a crucial step toward redefining healthcare through AI-driven drug discovery and biotechnology. By uniting AI innovation with biotech expertise, we’re not only advancing the fight against age-related diseases but also building a global ecosystem that empowers prevention, precision, and progress—delivering transformative therapies from Abu Dhabi to the world,” said Dr Fahed Al Marzooqi, Chief Executive Officer of M42’s Integrated Health Solutions platform and Acting Chief Executive Officer of M42’s AI Life Sciences platform.
Dr. Richard Marshall, Chief Executive Officer at Juvenescence, added: “We are delighted to be working together with M42. This powerful partnership will combine M42’s expertise in AI, technology, and genomics with Juvenescence’s unrivalled ability to discover and develop innovative drugs for age-related disease. Our work together will enable the creation of a unique pipeline of innovative therapeutics that will have enormous potential to target the underlying causes of age-related disease and improve the healthspan of patients globally.”
Building on Genomics and Biobanking Strength
Through this partnership, Juvenescence’s team—boasting more than 150 years of cumulative experience in drug discovery and development—will collaborate with M42 to build a cutting-edge therapeutics pipeline. This move builds on M42’s genomics capabilities developed in partnership with the Department of Health Abu Dhabi, including its support of the Emirati Genome Project (EGP), which has sequenced over 800,000 whole genomes and aims to reach one million.
M42’s Abu Dhabi Biobank (ADBB), with more than 900,000 samples, also stands as a critical asset in advancing biomedical research and supporting precision medicine efforts.
As Abu Dhabi continues to position itself as a global destination for health innovation, M42’s partnership with Juvenescence signals a proactive step in translating scientific discovery into clinical impact—bridging AI, biotech, and human health for a healthier, longer-living global population.
MedTech Malta 2025
Mark your calendar for 12–14 November as MedTech Malta returns to Valletta, uniting founders, investors, regulators, and innovators for three days of practical insights and purposeful networking. Whether you’re looking to pitch, partner, sponsor, or explore what’s next in MedTech, this is where momentum builds. Expect focused conversations, curated connections, and the much-anticipated Startup Pitch Competition. Interested in getting involved? Contact us at [email protected] to secure your spot in the programme and grab your early bird ticket before prices rise.
